ArticleInvestigative ophthalmology & visual science2026
Neuropilin-2 Deficiency Promotes Mitochondrial Dysfunction and NAD⁺-Dependent Cellular Senescence in Retinal Degeneration.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Retinal pigment epithelial (RPE) dysfunction is a central pathological feature of retinal degenerative diseases, leading to irreversible vision loss. RPE dysfunction is substantially driven by mitochondrial impairment and senescence. However, the upstream regulators of these processes remain largely undefined. This study investigated the role of neuropilin-2 (NRP2) in RPE homeostasis and explored mitochondrial-targeted therapy with echinacoside (ECH) as a potential intervention for retinal degeneration. Methods: RPE-specific Nrp2 conditional knockout mice were generated using AAV-VMD2-Cre and retinal morphology and function were assessed by fundus imaging, optical coherence tomography, histology, and electroretinogram (ERG). Cellular and metabolic phenotypes were examined in NRP2-deficient ARPE-19 cells and validated in vivo. RPE senescence, mitochondrial function, NAD⁺ metabolism, and sirtuin activity were analyzed, and the effects of ECH treatment were evaluated both in vitro and in vivo. Results: RPE-specific Nrp2 deletion resulted in progressive RPE atrophy, photoreceptor loss, and impaired ERG responses. NRP2 deficiency led to mitochondrial elongation, elevated ROS, membrane depolarization, and reduced NAD⁺/NADH ratios. Decreased NAD⁺ levels were accompanied by downregulation of SIRT1/SIRT3 and increased protein acetylation, promoting RPE senescence. Restoring NAD⁺ levels or ECH treatment rescued mitochondrial dysfunction and reduced senescence markers in vitro. Furthermore, in vivo ECH administration preserved retinal structure and visual function in NRP2-deficient mice. Conclusions: NRP2 is a critical regulator of mitochondrial integrity and NAD⁺ metabolism in the RPE. Its loss disrupts metabolic homeostasis, promoting RPE senescence and retinal degeneration. Targeting the NRP2-mitochondria-NAD⁺ axis with echinacoside represents a promising therapeutic strategy for preventing retinal degenerative diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.